Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-01-27

FDA Approved: TRIJARDY XR — Original Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved TRIJARDY XR, a fixed-dose combination tablet of empagliflozin, linagliptin, and metformin hydrochloride, in an original application. This provi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TRIJARDY XR (Empagliflozin, Linagliptin, Metformin hydrochloride)

Snippet

ORIG AP for TRIJARDY XR (EMPAGLIFLOZIN, LINAGLIPTIN, METFORMIN HYDROCHLORIDE)